”After years of research we suddenly realised how to combine our findings. It was a eureka moment.”

Introducing Amferia wound dressing for animal care — binds and kills bacteria without harming the body

How antimicrobial hydrogel can revolutionize clinical treatments

Binds and kills 99.99% of bacteria without harming the body – even resistant bacteria

Binds and kills 99.99% of bacteria without harming the body – even resistant bacteria

How it works:

For decades, we’ve known that antimicrobial peptides are potent killers of bacteria. Peptides carry a positive electrostatic charge, which naturally attracts the negative charge bacteria carry. Once attached, the knife-like structure of peptides puncture bacterial membranes, killing the cells.  

What hasn’t been known—until now—is how to protect vulnerable parts of the peptide from natural enzymes in the human body. In nature, peptides are fragile molecules. Enzymes can destroy them in seconds. To be effective bacteria killers, peptides need protection.  

To be effective bacteria killers, peptides need protection  

Amferia solves that problem with an innovative, patented hydrogel platform that encases peptides in a solid gel, leaving only the knife-like structure free to attract and puncture bacterial cells.

Because peptides kill bacteria in a physical—as opposed to chemical—process, Amferia products kill even bacteria that has become resistant to antibiotic drugs.

Amferia’s hydrogel stabilizes and protects the peptides for up to five days in biological environments, keeping them actively killing bacteria that entire time. Amferia harnesses peptides in a safe, stable, non-toxic and clinically applicable form, allowing them to kill bacteria without harming anything else in the body.

Amferia’s proprietary antimicrobial technology consists of bio-inspired and amphiphilic antibacterial polymers that target, rapidly bind and kill up to 99.99% of bacteria upon contact—including numerous strains of antibiotic resistant bacteria like MRSA and MDR E. Coli

The material is selective and targets only bacteria while being entirely non-toxic to the human and animal body. 

Now, Amferia has developed this platform into its first in-market product—wound dressing for animal care. Ultimately, the goal is to bring this technology into the market as new and effective products to treat patients at risk of acquiring dangerous skin and wound infections. 

Amferia’s approach to killing bacteria

  • 1. Binds and kills bacterial loads in seconds—including antibiotic resistant bacteria
  • 2. Highly potent and targets only bacteria
  • 3. Completely harmless to human and animal cells
  • 4. Does not release any antimicrobials into the wound environment

Using antimicrobial peptides in new ways mimicking the immune system

The science:

Derived from the mammalian immune system, antimicrobial peptides are powerful molecules that can rapidly and selectively kill bacteria—including antibiotic resistant bacteria—and prevent bacterial infections.

Until today, antimicrobial peptides have had poor stability

These peptides have been present in mammals for millions of years and have a unique way of killing bacteria by rapidly disrupting the bacteria’s cell membrane through something called electrostatic and amphiphilic interaction. You can think of peptides as a highly specialised soap-like molecule designed to kill bacterial cells by ripping off their skin. 

Antimicrobial peptides carry a net-positive charge and a molecular structure that includes hydrophobic and hydrophilic characteristics. These two factors allow peptides to attract bacterial cells—which carry a net-negative charge and are also amphiphilic—and bind to them, before puncturing their membrane and killing the cell.

Peptides destroy bacterial cells in a physical process, which means bacteria have a very low probability of evolving resistance the way they have been able to against antibiotics, which work chemically. 

Until today, antimicrobial peptides have had poor stability. In the past, their fragility has made antimicrobial peptides challenging for clinical applications. High doses of antimicrobial peptides were needed, which increased costs and, since at those doses peptides were classified as pharma products, prolonged the time-to-market.

As a result, past efforts to develop market-ready products featuring this valuable antimicrobial technology have faced substantial hurdles.

Amferia has solved this problem by implementing a scientifically robust approach that covalently and permanently bind antimicrobial peptides to the surface of a soft, ordered and amphiphilic hydrogel pad.

These permanent bonds protect the vulnerable portion of the peptide molecule and fix them in place, while leaving their bacteria-killing mechanism free to attract and destroy bacterial cells. They also ensure no peptides leak into the wound. Antimicrobial peptides fixed to an underlying hydrogel pad allowed Amferia to develop a safe, efficient and cost-effective design for an antimicrobial wound dressing.  

Amferia has solved this problem by permanently binding the peptides to an amphiphilic hydrogel

This design provides the needed balance between stability and activity.

The end-product is a singular material that does not leach or release any peptides or substances into the body, but rather acts locally as a contact-killing medical device—which will enable faster clinical translation.

Previous antimicrobial peptide technologies utilize peptides in their pristine form, which renders them inactive in a few minutes. Amferia’s innovation enables the bound peptides to remain stable and active for up to five days. Current testing indicates the product we’re developing for wound care will be shelf-stable for up to eighteen months, and potentially up to two years.

Read about our first product using the technology >

Years of research yield a breakthrough innovation


Amferia’s technology is born out of years of research performed at Chalmers University of Technology. The concept behind Amferia’s antibacterial properties are enabled by a new material known as amphiphilic antimicrobial hydrogel.

An amphiphilic substance is one that displays both hydrophilic and hydrophobic characteristics. Comprised of more than 70% water, the hydrogel is soft and flexible, making it useful for numerous medical applications.

Amferia’s technology is based on a new material known as amphiphilic antimicrobial hydrogels

The surface of amphiphilic hydrogel consists of antimicrobial peptides that are covalently and permanently bound to the hydrogels amphiphilic structure—forming a single material. The material interacts with bacterial cells and, disrupts the bacterial cell wall rapidly, effectively killing the bacteria.

Testing proves that the amphiphilic antimicrobial hydrogel does not release any substances into the wound or the environment. This singular material can be configured into antimicrobial products ranging from wound care dressings to antiseptic sprays to mechanically durable devices such as catheters and implants.  

To date, analysis confirms that Amferia amphiphilic antimicrobial hydrogel has up to 99.99% kill rate against multiple gram-negative and gram-positive bacterial strains, including MRSA, MDR E. Coli and Pseudomonas aeruginosa.

It has also been proven to be non-toxic to the body as per ISO 10993 biocompatibility evaluations, namely acute toxicity, cytotoxicity, skin sensitisation & irritation, implantation and material mediated pyrogenicity. 

Amferia's first product for human wound care and animal wound care has been developed for easy applicability and functionality, as proven in numerous pre-clinical and clinical studies. More products and broader applications are in the pipeline.

Read about possible applications of Amferia's innovation >

Amferia’s technology verified in scientific papers

Scientific evidence:

The antimicrobial efficacy of Amferia’s technology platform and its safety in lab and animal studies have been verified in numerous pre-clinical studies published in peer-reviewed scientific journals.

The studies describe evidence of Amferia’s technology through fluorescence microscopy against multiple strains of bacteria, including resistant bacteria. An animal infection study demonstrates the real-time effectiveness of Amferia hydrogel in eradicating bacteria from a wound. 

In 2022, Amferia’s technology platform was verified in a new form for potential spray-based applications. The base technology was reformulated as small particles that can be sprayed for applications in deep wounds. The results demonstrated excellent reduction of the broad bacterial bio burden including resistant bacteria up to 4 log reduction (or 99.99%) bacterial colonies. This study and others are now published in peer-reviewed scientific journals as listed below. 

Pre-clinical studies in peer-reviewed scientific journals

First human study

Clinical studies:

In a study involving 40 healthy volunteers, Amferia dressing was applied on the intact skin of the subjects’ lower arms. The study was a randomised, double-blinded, placebo-controlled evaluation of the efficacy of Amferia dressing on eradicating bacteria from a clinically relevant surface. 

The human skin is a source of bacteria for certain wound infections, for example in surgery wounds. The reduction of bacteria on skin after three hours of dressing application was examined. An average bacterial reduction by 1,000 times (i.e. 99.9%) was observed after application of Amferia wound dressing. In some cases where bacterial load was high, an almost 99.99% reduction was seen (as below).

The image below shows swab cultures from one sample and demonstrates the antimicrobial efficacy of the Amferia hydrogel wound dressing on human skin. The study and statistical analysis is now completed and published in the Journal of Wound Care.

Amferia raises SEK 6.2 million in pre-seed investment

January 22, 2020

Almi Invest, Chalmers Ventures, along with the British investor Corithinan Properties Ltd. and Let’s Deal Founder Alexander Hars have invested a total of SEK 6.2 million in the Gothenburg-based med-tech company Amferia, who has developed a wound care product with a patented material that actively combats infections and kills antibiotic-resistant bacteria.

“Every year, 700,000 people die globally as a result of infections caused by antibiotic-resistant bacteria and almost half of the infections begin with a simple wound on the skin. Amferia's wound care solution is a game-changer and will save lives”, says Louise Warme, Investment Manager at Almi Invest.

Amferia establishes R&D operations at AstraZeneca’s BioVentureHub

October 28, 2019

Amferia is very excited to move into the BioVentureHub, given the strong benefits of operating in a flourishing environment with state-of-the-art infrastructure dedicated to medtech and life science companies. We are also eager to be around so many experts within life science ranging from established to early-stage companies researching in biopharmaceuticals, medical devices and diagnostics. Amferia looks forward to be part of, learn and grow in this supportive and exciting community.

At the Annual Veterinary Hygiene Conference 2019

October 24, 2019

We had the pleasure to attend the annual Veterinary Hygiene Conference in Knivsta, Stockholm. One of the primary questions of this conference was about handling antibiotic resistant infections in animal wound care – a fast growing problem in Sweden and Globally. Many interesting & enlightening discussions with expert veterinary clinicians taught us a lot about the needs and challenges in animal wound care and how Amferia might expand its innovative solutions to help veterinary healthcare. Thanks for a great conference VVHF.

Amferia wins the Start-up of the Year award at Venture Cup Sweden 2019

September 20, 2019

The Jury's motivation for choosing Amferia as the winners! “With its disruptive solution, the team has the opportunity to shake several industries as they tackle one of humanity’s greatest global threats. By addressing a world problem, millions of lives will be saved. By changing the behavior of the consumer, there is also the potential to reform the market.”

Amferia receives the prestigious EU SME Instrument (Phase 1) grant from the European Union

August 1, 2019

Amferia receives the highly competitive and coveted EU SME Instrument Phase 1 grant of 50 000 Euros along with the valuable business network to take forward our technology into the market.

Amferia presents at Brilliant Minds conference 2019, Stockholm

June 15, 2019

Amferia was honoured to pitch as one of the ‘Next Brilliant in Tech‘ at Brilliant Minds 2019 held at Stockholm between 13-15 June. With esteemed guests like President Barack Obama, Secretary John Kerry, Greta Thunberg, the conference was an enlightening and inspiring event with much hope for the future.

The Recent UN Report on Antibiotic Resistance

May 3, 2019

The United Nations appointed Interagency Coordination Group on Antimicrobial Resistance (IACG) has presented its report on Recommendations to Combat Antimicrobial Resistance (AMR). It is clear from the report that AMR is a global and complex threat that needs to be addressed with extreme urgency and with care. Consistent, coordinated and conscious actions are demanded, especially from the World Goverments, Academia, Public, Healthcare-Industry and  Agriculture. A world where bacterial infections cannot be fought efficiently is a world of perils.

Here is an excerpt from the IACG report.

“The challenges of antimicrobial resistance are complex and multifaceted, but they are not insurmountable. Implementation of the recommendations in this report will help to save millions of lives, preserve antimicrobials for generations to come and secure the future from drug-resistant diseases.

But there is no time to wait.”

-IACG Report, April 29, 2019

Do take a minute and read the summary of this important report (English, pdf 653 kb)

Amferia featured in Göteborgs-Posten

February 8, 2019

New patch from Gothenburg kills bacteria in wounds. Read to know more

Amferia wins the Swedbank Rivstart 2018

February 7, 2019

Amferia is proud to become the winners of the annual entrepreneur competition hosted by Swedbank, Rivstart. From over 1825 applications, Amferia finished on top!

Amferia wins the Venture Day 2018, hosted by Chalmers Ventures

November 28, 2018

Amferia is proud to be named winners of the annual Pitch competition hosted by Chalmers Ventures.